ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Psychiatry · J Affect Disord · 2026-09-30

Network meta-analysis of RCTs in acute depression with mixed features: lurasidone 60-80 mg/day, lumateperone 42 mg/day and asenapine 15 mg/day beat placebo on symptoms in bipolar depression (22 studies, 5241 participants); lurasidone 40 mg/day did in major depression.

Meta-analysisn = 7,055
Fornaro et al. Pharmacological interventions for acute major depression and bipolar depression with mixed features: A systematic review and dose-related network meta-analysis across different age groups
Psychiatry · J Affect Disord · 2026-06-23

Network meta-analysis of 103 RCTs (20,941 participants) in acute bipolar depression: in low-risk-of-bias sensitivity analysis, lamotrigine 50 or 200 mg/day, quetiapine XR 150/300 mg/day and lumateperone 42 mg/day beat placebo on symptoms; none did on response or acceptability.

Meta-analysisn = 20,941
Fornaro et al. Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar depression: A systematic review and dose-related network meta-analysis across different age groups
Psychiatry · J Affect Disord · 2026-02-23

Post hoc analysis of a placebo-controlled trial in 383 patients with MDD or bipolar disorder and a depressive episode with mixed features: lumateperone 42 mg improved 9 of 10 MADRS items versus placebo at day 43; suicidal thoughts did not improve.

Secondary analysisn = 383
Yatham et al. The efficacy of lumateperone across symptoms of a major depressive episode with mixed features in patients with major depressive disorder and bipolar disorder: Post hoc analyses

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.